Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19

Xiao-Yu Zhang,1,* Tao Li,2,* Haibing Wu,3 Yun Ling,4 Zhi-Ping Qian,5 Liang Chen1 1Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 2Department of Tuberculosis Disease, Shanghai Public Health Clinical Center...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang XY, Li T, Wu H, Ling Y, Qian ZP, Chen L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	covid-19 sars-cov-2 proton pump inhibitors sars-cov-2 clearance hospital stay Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/5fcd1a3329024c6e89481fdc64822bee
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5fcd1a3329024c6e89481fdc64822bee
record_format	dspace
spelling	oai:doaj.org-article:5fcd1a3329024c6e89481fdc64822bee2021-12-02T14:14:59ZAnalysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-191178-7031https://doaj.org/article/5fcd1a3329024c6e89481fdc64822bee2021-02-01T00:00:00Zhttps://www.dovepress.com/analysis-of-the-effect-of-proton-pump-inhibitors-on-the-course-of-covi-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Xiao-Yu Zhang,1,* Tao Li,2,* Haibing Wu,3 Yun Ling,4 Zhi-Ping Qian,5 Liang Chen1 1Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 2Department of Tuberculosis Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 3Department of Neurosurgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 4Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 5Department of Severe Hepatopathy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China*These authors contributed equally to this workCorrespondence: Liang Chen; Xiao-Yu ZhangDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of ChinaTel +8618930810000; +8613052251333Email chenliang65@yeah.net; zhangxiaoyuPRC@163.comObjective: This study is to evaluate the effect of proton-pump inhibitors on the course of COVID-19.Methods: Clinical data of moderate COVID-19 patients admitted to the Shanghai Public Health Clinical Center for treatment from January 20, 2020, to March 16, 2020, were collected. A retrospective study was conducted and the patients were divided into two groups according to whether they used proton-pump inhibitors or not. The differences in SARS-CoV-2 clearance and hospital stay between the two groups were compared by Cox proportional hazards (PH) regression models and the propensity score matching method.Results: A total of 154 patients with moderate COVID-19 were included in this study, including 80 males (51.9%), 35 patients (22.7%) in the proton-pump inhibitor group, and 119 patients (77.3%) in the control group. In the proton-pump inhibitor group and the control group, the duration of the SARS-CoV-2 clearance was 7 days (95% CI, 6– 9) and 7 days (95% CI, 6– 11), and the duration of the hospital stay was 21 days (95% CI, 16– 25) and 20 days (95% CI, 15– 26), respectively. There was no significant difference between the both groups in the cumulative incidence of the SARS-CoV-2 clearance and the discharge, and the same results were obtained after the propensity score matching, all P > 0.05. There was no significant association between the use of proton-pump inhibitors and the duration of SARS-CoV-2 clearance, according to univariate analysis (HR, 1.309; 95% CI, 0.893– 1.918) and multivariate analysis (HR, 1.575; 95% CI, 0.993– 2.499). There was no significant association between the use of proton-pump inhibitors and the duration of hospital stay for COVID-19, according to univariate analysis (HR, 1.044; 95% CI, 0.714– 1.528) and multivariate analysis (HR, 1.064; 95% CI, 0.651– 1.740).Conclusion: The use of proton-pump inhibitors has no effect on prolonging or shortening the course of adults hospitalized with COVID-19.Keywords: COVID-19, SARS-CoV-2, proton-pump inhibitors, SARS-CoV-2 clearance, hospital stayZhang XYLi TWu HLing YQian ZPChen LDove Medical Pressarticlecovid-19sars-cov-2proton pump inhibitorssars-cov-2 clearancehospital stayPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 287-298 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 sars-cov-2 proton pump inhibitors sars-cov-2 clearance hospital stay Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	covid-19 sars-cov-2 proton pump inhibitors sars-cov-2 clearance hospital stay Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Zhang XY Li T Wu H Ling Y Qian ZP Chen L Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
description	Xiao-Yu Zhang,1,* Tao Li,2,* Haibing Wu,3 Yun Ling,4 Zhi-Ping Qian,5 Liang Chen1 1Department of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 2Department of Tuberculosis Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 3Department of Neurosurgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 4Department of Infectious Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China; 5Department of Severe Hepatopathy, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of China*These authors contributed equally to this workCorrespondence: Liang Chen; Xiao-Yu ZhangDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, People’s Republic of ChinaTel +8618930810000; +8613052251333Email chenliang65@yeah.net; zhangxiaoyuPRC@163.comObjective: This study is to evaluate the effect of proton-pump inhibitors on the course of COVID-19.Methods: Clinical data of moderate COVID-19 patients admitted to the Shanghai Public Health Clinical Center for treatment from January 20, 2020, to March 16, 2020, were collected. A retrospective study was conducted and the patients were divided into two groups according to whether they used proton-pump inhibitors or not. The differences in SARS-CoV-2 clearance and hospital stay between the two groups were compared by Cox proportional hazards (PH) regression models and the propensity score matching method.Results: A total of 154 patients with moderate COVID-19 were included in this study, including 80 males (51.9%), 35 patients (22.7%) in the proton-pump inhibitor group, and 119 patients (77.3%) in the control group. In the proton-pump inhibitor group and the control group, the duration of the SARS-CoV-2 clearance was 7 days (95% CI, 6– 9) and 7 days (95% CI, 6– 11), and the duration of the hospital stay was 21 days (95% CI, 16– 25) and 20 days (95% CI, 15– 26), respectively. There was no significant difference between the both groups in the cumulative incidence of the SARS-CoV-2 clearance and the discharge, and the same results were obtained after the propensity score matching, all P > 0.05. There was no significant association between the use of proton-pump inhibitors and the duration of SARS-CoV-2 clearance, according to univariate analysis (HR, 1.309; 95% CI, 0.893– 1.918) and multivariate analysis (HR, 1.575; 95% CI, 0.993– 2.499). There was no significant association between the use of proton-pump inhibitors and the duration of hospital stay for COVID-19, according to univariate analysis (HR, 1.044; 95% CI, 0.714– 1.528) and multivariate analysis (HR, 1.064; 95% CI, 0.651– 1.740).Conclusion: The use of proton-pump inhibitors has no effect on prolonging or shortening the course of adults hospitalized with COVID-19.Keywords: COVID-19, SARS-CoV-2, proton-pump inhibitors, SARS-CoV-2 clearance, hospital stay
format	article
author	Zhang XY Li T Wu H Ling Y Qian ZP Chen L
author_facet	Zhang XY Li T Wu H Ling Y Qian ZP Chen L
author_sort	Zhang XY
title	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
title_short	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
title_full	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
title_fullStr	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
title_full_unstemmed	Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19
title_sort	analysis of the effect of proton-pump inhibitors on the course of covid-19
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/5fcd1a3329024c6e89481fdc64822bee
work_keys_str_mv	AT zhangxy analysisoftheeffectofprotonpumpinhibitorsonthecourseofcovid19 AT lit analysisoftheeffectofprotonpumpinhibitorsonthecourseofcovid19 AT wuh analysisoftheeffectofprotonpumpinhibitorsonthecourseofcovid19 AT lingy analysisoftheeffectofprotonpumpinhibitorsonthecourseofcovid19 AT qianzp analysisoftheeffectofprotonpumpinhibitorsonthecourseofcovid19 AT chenl analysisoftheeffectofprotonpumpinhibitorsonthecourseofcovid19
_version_	1718391730002198528

Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19

Ejemplares similares